Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:38:01 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:AGRX from 2023-04-27 to 2024-04-26 - 34 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-03-28 08:05U:AGRXNews ReleaseAgile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
2024-03-25 16:30U:AGRXNews ReleaseAgile Therapeutics Announces Delisting from Nasdaq
2024-03-21 06:35U:AGRXNews ReleaseCorrection - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
2024-03-20 08:15U:AGRXNews ReleaseAgile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024
2024-03-13 07:31U:AGRXNews ReleaseAgile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
2024-02-22 09:01U:AGRXNews ReleaseAgile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
2024-02-15 16:30U:AGRXNews ReleaseAgile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders ¢ € ™ Equity Continued Listing Requirement & Provides Performance Update
2024-01-23 09:29U:AGRXNews ReleaseThe Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost
2023-12-12 08:01U:AGRXNews ReleaseAgile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act ¢ € ™s No-Cost Contraceptive Coverage Requirement
2023-11-22 09:02U:AGRXNews ReleaseAgile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024
2023-11-09 08:05U:AGRXNews ReleaseAgile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-10-26 08:05U:AGRXNews ReleaseAgile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023
2023-10-04 16:30U:AGRXNews ReleaseAgile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
2023-09-28 09:02U:AGRXNews ReleaseAgile Therapeutics (NASDAQ: AGRX) Upgraded To ¢ € œBuy ¢ €  Rating By Analysts At Maxim Group
2023-09-05 08:06U:AGRXNews ReleaseAgile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-17 09:02U:AGRXNews ReleaseAgile Says It's On Track To Hit $25-$30 Million Net Annual Revenue After A Strong Performance In Its Second Quarter
2023-08-09 08:05U:AGRXNews ReleaseAgile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
2023-07-26 08:30U:AGRXNews ReleaseAgile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023
2023-07-19 09:01U:AGRXNews ReleaseThis Reproductive Health Company's Weekly Contraceptive Patch Can Reach Millions of Women Thanks to a Partnership With Afaxys
2023-07-18 09:02U:AGRXNews ReleaseAgile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of Women
2023-07-11 09:16U:AGRXNews ReleaseAgile Sees Renewed Hope For Even Broader Adoption Of Its Weekly Birth Control Patch After Biden ¢ € ™s Latest Executive Order Expanding Contraceptive Coverage
2023-07-05 09:01U:AGRXNews ReleaseH.C. Wainwright Reiterates Buy Rating For Agile Therapeutics (NASDAQ: AGRX), Citing Growing Demand For Twirla, A Weekly Low Dose Birth Control Patch
2023-07-03 09:03U:AGRXNews ReleaseThis Women's Healthcare Company Raised $7.5 Million In A Public Offering And Says It's Targeting $25 To $30 Million Net Revenue By End Of 2023
2023-06-30 09:01U:AGRXNews ReleaseAgile Therapeutics Expects Its Innovative Once-A-Week Birth Control Patch To Drive Revenues Of $25-30 Million In 2023 - What Is The Hype All About?
2023-06-28 09:05U:AGRXNews ReleaseThe Overturning of Roe v. Wade Has Changed the Landscape of Birth Control; Smaller Companies are now an Integral Part of Care
2023-06-26 08:01U:AGRXNews ReleaseAgile Therapeutics Announces the Availability of Twirla ‚ ® to MMCAP Infuse Members
2023-06-23 12:05U:AGRXNews ReleaseAgile Therapeutics Commends the Biden Administration ¢ € ™s Commitment to Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services
2023-06-15 16:05U:AGRXNews ReleaseAgile Therapeutics Announces the Availability of Twirla ‚ ® through FPA Women ¢ € ™s Health
2023-06-13 16:05U:AGRXNews ReleaseAgile Therapeutics Announces New Agreement with vitaCare ‚ ® Prescription Services to Improve Access to Twirla ‚ ®
2023-05-25 16:05U:AGRXNews ReleaseAgile Therapeutics Announces Closing of $7.5 Million Public Offering
2023-05-22 20:00U:AGRXNews ReleaseAgile Therapeutics Announces Pricing of $7.5 Million Public Offering
2023-05-11 16:05U:AGRXNews ReleaseAgile Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate Update
2023-05-08 08:00U:AGRXNews ReleaseAgile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023
2023-04-28 08:01U:AGRXNews ReleaseAgile Therapeutics Announces Preliminary Expectations for First Quarter 2023